1. Synthesis and in Vitro Testing of a Pyropheophorbide-a-Fullerene Hexakis Adduct Immunoconjugate for Photodynamic Therapy
- Author
-
Eugeny A. Ermilov, and Andreas Hirsch, Andreas Mölich, Beate Röder, Fiorenza Rancan, Fritz Böhm, Norbert Jux, and Matthias Helmreich
- Subjects
Chlorophyll ,Drug ,Immunoconjugates ,Lymphoma, B-Cell ,Carrier system ,Cell Survival ,Stereochemistry ,T-Lymphocytes ,medicine.medical_treatment ,media_common.quotation_subject ,Biomedical Engineering ,Pharmaceutical Science ,Antineoplastic Agents ,Bioengineering ,Photodynamic therapy ,Cell Line ,Adduct ,Antibodies, Monoclonal, Murine-Derived ,chemistry.chemical_compound ,medicine ,Humans ,Photosensitizer ,Cell Proliferation ,media_common ,Pharmacology ,B-Lymphocytes ,Drug Carriers ,Photosensitizing Agents ,Chemistry ,Organic Chemistry ,Antibodies, Monoclonal ,Antigens, CD20 ,Immunoconjugate ,Malonate ,Photochemotherapy ,Fullerenes ,Rituximab ,Selectivity ,Biotechnology - Abstract
The employment of carriers to enhance drug selectivity is one of the strategies to increase the efficacy and reduce the side effects of antitumor therapy. The concept of a modular carrier system (MCS) was developed to construct a complex drug having a high efficacy and selectivity. An MCS employs diverse units or modules: beside the therapeutic unit, an addressing unit (e.g., an antibody) serves to direct the drug to its target, and a multiplying unit has the role of increasing the number of biological active moieties the system can carry. In this paper, we report on the synthesis of a modular carrier system in which the role of multiplying unit is given to a [5:1]fullerene hexakis adduct. This fullerene hexaadduct has five malonate spacers which can bind two therapeutic units (the photosensitizer pyropheophorbide-a) each, for a total of ten, and a longer malonate spacer which serves for the conjugation to the addressing unit, the monoclonal antibody rituximab. Confocal microscopy studies using Epstein-Barr virus-transformed B-lymphocytes and Jurkat cells showed that the antibody conjugate conserves the affinity for its receptor (CD20) and its selectivity toward CD20 positive B-lymphocytes. On the contrary, the antibody-free complex did not show any bounding or intracellular uptake.
- Published
- 2007
- Full Text
- View/download PDF